BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 32519423)

  • 21. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
    Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
    Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
    Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
    Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
    Yu X; Munoz-Sagredo L; Streule K; Muschong P; Bayer E; Walter RJ; Gutjahr JC; Greil R; Concha ML; Müller-Tidow C; Hartmann TN; Orian-Rousseau V
    Blood; 2021 Sep; 138(12):1067-1080. PubMed ID: 34115113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
    Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
    Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
    Chen L; Li D; Guo X; Cheng C; Wei X
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting NF-κB-dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells.
    Zhu S; Liu J; Kang R; Yang M; Tang D
    Biochem Biophys Res Commun; 2021 Jul; 562():55-61. PubMed ID: 34034094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
    Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
    Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
    Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenstrom macroglobulinemia cells devoid of BTK
    Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
    Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.
    Niu X; Rothe K; Chen M; Grasedieck S; Li R; Nam SE; Zhang X; Novakovskiy GE; Ahn YH; Maksakova I; Lai S; Zhang H; Yan J; Liu H; Zhao Y; Wu D; Ge Y; Wasserman WW; Rouhi A; Kuchenbauer F; Yip CK; Zhang Z; Jiang X
    Blood; 2021 Jul; 137(26):3641-3655. PubMed ID: 33786587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.
    Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y
    Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
    Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
    J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.